Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

ResMed

RMD Healthcare Unknown Updated July 31, 2026
$211.00
52W $180.27 – $293.81
57/100
$30.60B
20.3
0.78
AI Committee Verdict
Watch
Conviction: Moderate · 71% agreement · 7 analysts
+23.2%
-14.4%
1.61:1
Moderate

Is RMD Bullish or Bearish?

Mixed. Innellis AI committee rates ResMed (RMD) Watch with a composite score of 57/100 , based on 7 analysts with 71% agreement. Last updated July 31, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +2.66 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -17.34 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

Some positive signals exist — news sentiment is positive (+0.39 across 6 articles, 14d) — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.

Bull & Bear Case

Bull Case
  • ROE of 24.4% shows genuine earnings power backing the valuation — Value
  • MACD histogram positive -- bullish momentum — Technical
  • Low leverage (debt-to-equity 0.11) -- balance sheet can absorb a shock — Risk
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
  • News sentiment is positive (+0.39 across 6 articles, 14d) — News
Bear Case
  • Price-to-book of 6.3x prices in significant intangible value — Value
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • Bollinger bandwidth of 16.2% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of July 31, 2026
Overall Committee Score
57/100
Agreement
71%
Analysts
7
Conviction
Moderate
Sector Rank
Top 31%
of 93 Healthcare peers
Value Analyst neutral
59 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 24.4% shows genuine earnings power backing the valuation
− Price-to-book of 6.3x prices in significant intangible value
Growth Analyst neutral
50 / 100 · Moderate confidence
Moderate growth -- present but not remarkable
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
Risk Analyst bullish
62 / 100 · Moderate confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.11) -- balance sheet can absorb a shock
− Bollinger bandwidth of 16.2% signals elevated volatility
Macro Analyst neutral
58 / 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
70 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.39 across 6 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 57.4 to 57.3.

Analyst-level changes:
  • Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
  • News Analyst: +1 bullish signal(s).
  • Portfolio Manager: +2 bearish signal(s).
  • Risk Analyst: +1 bearish signal(s).
  • Technical Analyst: score 48->58 (+10).

Comparing 2026-07-30 to 2026-07-31 (1 day apart).

Technical Analysis

RSI (14)
62.7
Neutral
MACD Histogram
1.435
Bullish Momentum
Trend Direction
Sideways
Weekly: Downtrend
Market Structure
Mixed
Support
$180.58
Resistance
$259.98
Bollinger %B
0.73
Inside Bands
Price vs Moving Averages
EMA 9
$205.50 Above
EMA 21
$202.71 Above
EMA 50
$203.43 Above
EMA 200
$225.81 Below

Fundamental Analysis

Valuation
72
Growth
63
Profitability
1
Financial Health
100
Cash Flow
37
Valuation
P/E Ratio 20.3×
P/B Ratio 4.76×
PEG Ratio 1.27
Dividend Yield 0.01%
52W High $293.81
52W Low $180.27
Quality & Growth
ROE 23.5%
ROA 17.1%
Gross Margin 61.7%
Operating Margin 34.3%
Revenue Growth YoY
Debt / Equity 0.13
AI Fundamental Assessment
P/E ratio of 20.3 (inexpensive relative to a 15-40x range); Price-to-book of 4.8x; PEG ratio of 1.3 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.2%; Return on assets of 0.2%; Net margin of 0.3%; Gross margin of 0.6%; Current ratio of 3.01 (healthy short-term liquidity); Debt-to-equity of 0.13; Free cash flow margin of 0.9% (thin cash generation); Free cash flow per share is positive (11.94); Most recent quarter beat estimates by 1.3%; 2 consecutive earnings beats; EPS growth decelerating (+10.2% -> +1.8% QoQ); Analyst estimates rising over recent quarters
Get the Full RMD Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore RMD Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime